News for STERIS plc (STEN.MX)

Summary Steris PLC (STE), a global leader in infection prevention and healthcare solutions, has announced a conference call to discuss its fiscal 2026 first-qua

DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ('STERIS” or the 'Company”) announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

KeyBanc analyst Brett Fishbin has increased the price target for Steris (STE) to $288, up from $277, while maintaining an Overweight rating on the stock. The fi

STERIS is set to report its second-quarter results next month, and analysts are projecting a double-digit rise in earnings.

Key Takeaways: Morgan Stanley upgrades Steris (STE) to Overweight with a new target price of $276. Steris demonstrates minimal tariff and macroeconomic r

In a recent development, Morgan Stanley has upgraded its rating for Steris (STE), a leading provider in the healthcare sector. The investment firm, represented

Morgan Stanley has upgraded Steris (STE) from an Equal Weight to an Overweight rating, raising its price target to $276 from the previous $260. The decision ref

STERIS plc (STE) has announced that Dr. Richard Steeves will retire from the company's Board of Directors, effective at the conclusion of the Annual General M

STERIS Corp. (STE) secures a $450 million contract, extending its military and federal agreement until 2030. Analysts project an average price target of

Steris (STE) has successfully obtained a contract modification worth up to $450 million, extending the agreement for an additional five years. This extension fa

STERIS has outpaced the broader healthcare sector over the past year and analysts are reasonably bullish on its future prospects.

Strong market leadership in infection prevention and sterilization services.Expansive product and service offerings catering to healthcare and life sciences se

Jefferies initiated coverage of Steris PLC (NYSE:STE) on May 28 with a ‘Hold’ rating and a $263 price target. The research firm reiterated that the company could come under pressure due to the risk of over 14 million Medicaid and Health Insurance individuals losing coverage. Jefferies expects STERIS to grow revenue by 8% in 2026, […]

Steris (STE) has recently been the subject of a new analyst coverage by Jefferies, a well-known financial services company. The firm has initiated its coverage

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

An analysis by Jefferies' David Windley has initiated coverage on Steris (STE), assigning it a Hold rating with a price target of $263. The company is expected

In recent developments, Morgan Stanley has adjusted its price target for Steris (STE), increasing it from a previous $240.00 to $260.00 USD. This adjustment rep

Steris PLC (STE) has recently been in the spotlight, drawing interest from investors and financial analysts due to its robust financial stance. With shares curr

Citizens JMP has adjusted its price target for Steris (STE) upwards to $280 from the previous $265, while maintaining an Outperform rating for the stock. Steris